NeoStem, the New York-based developer and manufacturer of cell therapies, will pick up another California plant with its all-stock acquisition of California Stem Cell, which it announced this week.
With growing demand for eye drugs in Asia, Novartis' Alcon unit wants to have the capacity to sell into that market. To be able to do that, the company has opened a new plant in Singapore to make a variety of its eye drugs.
A U.K. plant that the former Patheon was ready to bail on two years ago will now get a $300 million shot in the arm. It and client Pacira will partner on manufacturing suites to provide additional capacity to produce Pacira's analgesic, Exparel.
Novartis' vaccine manufacturing site in Holly Springs, NC, is one of three backed by U.S. authorities which they can draft into service in the event of a pandemic. And it should be the first of the three to go online, according to a new report.
Japanese drugmaker Kyowa Hakko Kirin, which develops its own drugs and is in a partnership with Fuji to make biosimilars, has completed construction on a new active pharmaceutical plant for biologics.
Mitsubishi last year invested in India's Neuland Laboratories, which in turn was to build new plants that would produce active pharmaceutical ingredients for the Japanese company. The first of those plants is now online.
UPM Pharmaceuticals bought a former King Pharmaceuticals plant in Tennessee from Pfizer last year, with the idea that the large facility would allow it to take on commercial contracts. Now, it has that capacity.
Indian drugmaker Aurobindo has completed its $41 million acquisition of 7 Actavis active pharmaceutical ingredient facilities across Western Europe.
U.S. drugmaker Alexion opened its first operation in Ireland last year, creating a logistics center there. Then came plans for a vial-filling facility. Now it has announced a third project there, another to handle supply chain chores.
FDA inspectors paid a return visit to Hikma Pharmaceutical's New Jersey plant in February and found everything satisfactory. The FDA has now issued a closeout letter for the plant that was cited with a warning letter more than two years ago.